Comparison of 2 NovoFine® Needles on the Reflux of Insulin
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial is conducted in Europe. This trial aims to ensure that there is no substantial clinically relevant difference between the two Novo Nordisk needles NovoFine® 6 x 0.30 mm and NovoFine® 8 x 0.30 mm on reflux of insulin back to the surface of cutis.
Condition or disease
DiabetesDiabetes Mellitus, Type 1Delivery Systems
Device: NovoFine® needle 6 mmDevice: NovoFine® needle 8 mm
Insulin Leakage and Pain Perception in IDDM Children or Adolescents, Where the Injections Are Performed With NovoFine™ 6 x 0.30 mm Needles and NovoFine® 8 x 0.30 mm Needles: An Open, Randomized, Two-period Cross-over, Multi-centre, Phase IIIb Trial at 4 Centres
Actual Study Start Date
January 20, 1998
Actual Primary Completion Date
July 27, 1998
Actual Study Completion Date
July 27, 1998
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
10 Years to 17 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Children/adolescents with type 1 diabetes mellitus
Usage of NovoPen® 1.5 for at least 3 months
Duration of insulin treatment more than 1 year
Normal weight according to Tanner scales
The means of the last 2 HbA1c measurements taken within the last 6 months must be less than 10.5%
Pregnancy or desire to become pregnant
Clinical relevant peripheral neuropathy as judged by the investigators
Pronounced lipodystrophy in accordance with investigator's evaluation
Use of drugs that can influence the trial
Coagulation disorders (use of anti-coagulants)
Serious, chronic diseases, making it highly unlikely that the subject can complete the trial